Globus Medical, Inc.
Globus Medical, Inc. (GMED) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gmed · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Globus Medical, Inc. (GMED) measures how much investors pay for each dollar of the company's trailing earnings. GMED's current PE ratio of 18.46x is calculated by dividing its stock price of $80.00 by its TTM earnings per share of $4.33. −65.6% discount vs 5Y avg 53.6x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2009 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 17 fiscal years · Front-end computedMinQ1 · 25%27.1x
MedianQ3 · 75%109.0x
Max
At 18.46x, GMED's current P/E is lower than in 18% of its annual fiscal year readings over the past 17 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Globus Medical, Inc.You GMED | $10.8B | 18.46x | -7.9% | $4.33 |
 Align Technology, Inc. ALGN | $12.0B | 27.60x | +37.7% | $5.66 |
 AptarGroup, Inc. ATR | $7.2B | 20.41x | +1.8% | $5.97 |
 Bio-Rad Laboratories, Inc. BIO | $8.0B | 10.87x | -45.8% | $27.87 |
 DaVita Inc. DVA | $12.3B | 13.10x | -34.7% | $8.67 |
 Grifols, S.A. GRFS | $6.5B | 14.03x | -30.0% | $0.57 |
 HealthEquity, Inc. HQY | $7.4B | 34.29x | +71.0% | $2.50 |
Industry Average 6 peers with valid PE | — | 20.05x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 21.94x | $3.98 | -79.9% | |
2024-12-31 FY2024 | 109.01x | $0.76 | +122.3% | |
2023-12-31 FY2023 | 49.05x | $1.09 | +25.0% | |
2022-12-31 FY2022 | 39.24x | $1.89 | -19.5% | |
2021-12-31 FY2021 | 48.75x | $1.48 | -22.4% | |
2020-12-31 FY2020 | 62.86x | $1.04 | +67.1% | |
2019-12-31 FY2019 | 37.61x | $1.57 | +38.9% | |
2018-12-31 FY2018 | 27.07x | $1.60 | -26.5% | |
2017-12-31 FY2017 | 36.85x | $1.12 | +62.0% | |
2016-12-31 FY2016 | 22.74x | $1.09 | -3.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Globus Medical, Inc. (GMED) measures how much investors pay for each dollar of the company's trailing earnings. GMED's current PE ratio of 18.46x is calculated by dividing its stock price of $80.00 by its TTM earnings per share of $4.33.
Frequently asked questions
GMED pe ratio · 6 questionsGMED's current PE ratio is 18.46x as of 2026-06-08, based on a stock price of $80.00 and TTM EPS of $4.33. Data sourced from Financial Modeling Prep via GMED's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Globus Medical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08